CN103919885B - A kind of preparation method of soft capsule for nasosinusitis and application - Google Patents
A kind of preparation method of soft capsule for nasosinusitis and application Download PDFInfo
- Publication number
- CN103919885B CN103919885B CN201410169286.6A CN201410169286A CN103919885B CN 103919885 B CN103919885 B CN 103919885B CN 201410169286 A CN201410169286 A CN 201410169286A CN 103919885 B CN103919885 B CN 103919885B
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- nasosinusitis
- preparation
- flos
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 241000628997 Flos Species 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 239000009670 cang er zi wan Substances 0.000 claims abstract description 19
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 18
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 16
- 239000003549 soybean oil Substances 0.000 claims abstract description 16
- 230000004663 cell proliferation Effects 0.000 claims abstract description 13
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 11
- 206010018338 Glioma Diseases 0.000 claims abstract description 11
- 230000001629 suppression Effects 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000084 colloidal system Substances 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 7
- 206010010774 Constipation Diseases 0.000 abstract description 8
- 229960004756 ethanol Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- RBRPTFMVULVGIC-ZTIIIDENSA-N Xanthatin Chemical compound C1C=C(\C=C\C(C)=O)[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]21 RBRPTFMVULVGIC-ZTIIIDENSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RBRPTFMVULVGIC-UHFFFAOYSA-N xanthatin Natural products C1C=C(C=CC(C)=O)C(C)CC2OC(=O)C(=C)C21 RBRPTFMVULVGIC-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of preparation method of soft capsule for nasosinusitis, be made up as crude drug in right amount of Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, soybean oil, employing supercritical extraction is prepared from, content is improved a lot, dose reduces, and present invention also offers the application of soft capsule for nasosinusitis in preparation suppression human glioma cell's SF295 cell proliferation and constipation medicine.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicine preparation, be specifically related to a kind of preparation method and application of soft capsule for nasosinusitis.
Background technology
Soft capsule for nasosinusitis is recorded in ministry standard, prescription is that Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, soybean oil are appropriate, the above five tastes, Flos Lonicerae, Flos Chrysanthemi Indici, Flos Magnoliae extract volatile oil 4 hours, the another device of aqueous solution after distillation is collected, medicinal residues and Fructus Xanthii add 8 times amount soak by water secondaries, each 3 hours, collecting decoction, filtered, filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.10 ~ 1.20 (80 DEG C), adds ethanol and makes alcohol content be 60%, stirs, leave standstill, filter; Precipitation uses 60% washing with alcohol, and washing liquid is incorporated in filtrate.Radix Rubiae, according to the percolation (Chinese Pharmacopoeia version in 2010 annex I O) under fluid extract and extractum item, is used 70% ethanol as solvent, floods after 24 hours, slowly percolation, collects 12 times amount percolates, merges with above-mentioned filtrate, reclaim ethanol and be concentrated into the thick paste that relative density is about 1.35 (60 DEG C), spraying into above-mentioned volatile oil, it is appropriate to add soybean oil, mixing, with colloid mill grinding, is chilled to room temperature, be pressed into soft capsule 1000, dry, deoil, dry, to obtain final product.
In prior art, not yet there is soft capsule for nasosinusitis extracting the report adopting supercritical technology in preparation, and adopt the method for vapor distillation and soak by water, technique is coarse, backward, and impurity is many, causes patient's consumption excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
Goal of the invention: in order to solve the problem, the object of the present invention is to provide a kind of preparation method of soft capsule for nasosinusitis.
Another object of the present invention is to provide a kind of soft capsule for nasosinusitis to suppress the application in human glioma cell's SF295 cell proliferation and constipation medicine in preparation.
Technical scheme: the object of the invention is by following scheme realize:
A kind of preparation method of soft capsule for nasosinusitis, be made up as crude drug in right amount of Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, soybean oil, described method is made up of the following step: Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO2 flow 1-3m1/g crude drug min, extraction time 150-180min, obtains supercritical extract, and it is appropriate to add soybean oil, mixing, with colloid mill grinding, is chilled to room temperature, be pressed into soft capsule 1000, dry, deoil, dry, to obtain final product.
The preparation method of above-mentioned a kind of soft capsule for nasosinusitis, described CO
2the percent by volume that supercritical extraction entrainer accounts for total extractant is 5%.
The preparation method of above-mentioned a kind of soft capsule for nasosinusitis, described CO
2the extracting pressure 20MPa of supercritical extraction, temperature 40 DEG C, CO
2flow 2ml/g crude drug min, extraction time 160min.
Above-mentioned a kind of soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation, soft capsule for nasosinusitis is by by Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, soybean oil is made as crude drug in right amount, preparation method is made up of the following step: get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g joins in CO2 supercritical extraction device, ethanol is as entrainer, the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO2 flow 1-3m1/g crude drug min, extraction time 150-180min, obtain supercritical extract, add soybean oil appropriate, mixing, grind with colloid mill, be chilled to room temperature, be pressed into soft capsule 1000, dry, deoil, dry, obtain.
Above-mentioned a kind of soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation, CO described in soft capsule for nasosinusitis preparation method
2the percent by volume that supercritical extraction entrainer accounts for total extractant is 5%.
Above-mentioned a kind of soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation, CO described in soft capsule for nasosinusitis preparation method
2the extracting pressure 20MPa of supercritical extraction, temperature 40 DEG C, CO
2flow 2ml/g crude drug min, extraction time 160min.
The application of above-mentioned soft capsule for nasosinusitis in preparation treatment constipation medicine, soft capsule for nasosinusitis is by by Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, soybean oil is made as crude drug in right amount, preparation method is made up of the following step: get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g joins in CO2 supercritical extraction device, ethanol is as entrainer, the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO2 flow 1-3m1/g crude drug min, extraction time 150-180min, obtain supercritical extract, add soybean oil appropriate, mixing, grind with colloid mill, be chilled to room temperature, be pressed into soft capsule 1000, dry, deoil, dry, obtain.
Above-mentioned soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation, CO described in soft capsule for nasosinusitis preparation method
2the percent by volume that supercritical extraction entrainer accounts for total extractant is 5%.
Above-mentioned soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation, CO described in soft capsule for nasosinusitis preparation method
2the extracting pressure 20MPa of supercritical extraction, temperature 40 DEG C, CO
2flow 2ml/g crude drug min, extraction time 160min.
In prior art, the every sheet 0.34g of former soft capsule for nasosinusitis, each 3-4 grain, 3 times on the one, adopt the every sheet 0.3g of soft capsule for nasosinusitis that the present invention is prepared into, but the medical material amount contained is about original 2 times, therefore only needs 2 at every turn, within 1st, take 3 times, under the condition with more active component, greatly reduce dose.
The comparison of Xanthatin content in soft capsule for nasosinusitis prepared by test one, distinct methods
1, instrument and reagent soft capsule for nasosinusitis of the present invention: by the preparation of embodiment 3 method, get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 20MPa, temperature 40 DEG C, CO
2flow 2m1/g crude drug min, extraction time 160min, obtains supercritical extract, adds soybean oil in right amount, mixing, with colloid mill grinding, is chilled to room temperature, is pressed into soft capsule 1000, dry, deoils, dries, to obtain final product, every 0.3g.Former soft capsule for nasosinusitis, by the preparation of ministry standard method, gets Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, makes 1000 through extracting, dry, deoils, dries, to obtain final product, every 0.34g.Agilent1200 high performance liquid chromatograph; METTLER AE240 electronic analytical balance; Xanthatin standard substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
Chromatographic condition and system suitability: be filler with octadecylsilane chemically bonded silica; Methanol-water (55:45) is mobile phase; Determined wavelength is 278nm.Number of theoretical plate calculates by Xanthatin peak, should be not less than 3000.
The preparation of reference substance solution: precision takes at 60 DEG C of drying under reduced pressure Xanthatin reference substance of 4 hours appropriate, adds methanol and makes the solution of every 1ml containing 18 μ g, to obtain final product.
The preparation of need testing solution: get soft capsule for nasosinusitis of the present invention and former soft capsule for nasosinusitis, porphyrize, mixing, get 1g, accurately weighed, precision adds 70% ethanol 20ml, close plug, and supersound process 10 minutes is centrifugal, gets supernatant, to obtain final product.
Algoscopy is accurate respectively draws reference substance solution and each 20 μ l of need testing solution, injection liquid chromatography, measures, to obtain final product.
3, result
Result shows, in soft capsule for nasosinusitis of the present invention, the content of Xanthatin is 0.89mg/ grain; And the content of Xanthatin is 0.43mg/ grain in former soft capsule for nasosinusitis, when dose reduces, Xanthatin content improves a lot.
Above-mentioned research shows, adopts the soft capsule for nasosinusitis prepared of the present invention, and active constituent content is higher than the standby soft capsule for nasosinusitis of ministry standard legal system, and dose can reduce.
Detailed description of the invention
Form by the following examples, foregoing of the present invention is described in further detail again, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g join in CO2 supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 15MPa, temperature 30 DEG C, CO
2flow 1m1/g crude drug min, extraction time 150min, obtains supercritical extract, adds soybean oil in right amount, mixing, with colloid mill grinding, is chilled to room temperature, is pressed into soft capsule 1000, dry, deoils, dries, to obtain final product.
Embodiment 2
Get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 30MPa, temperature 50 C, CO
2flow 3m1/g crude drug min, extraction time 180min, obtains supercritical extract, adds soybean oil in right amount, mixing, with colloid mill grinding, is chilled to room temperature, is pressed into soft capsule 1000, dry, deoils, dries, to obtain final product.
Embodiment 3
Get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 20MPa, temperature 40 DEG C, CO
2flow 2m1/g crude drug min, extraction time 160min, obtains supercritical extract, adds soybean oil in right amount, mixing, with colloid mill grinding, is chilled to room temperature, is pressed into soft capsule 1000, dry, deoils, dries, to obtain final product.
Test two: soft capsule for nasosinusitis suppresses the experimentation data of SF295 cell proliferation
1 experiment material
1.1 experiment cell strains
Human glioma cell SF295 cell, Nanjing Medical University's laboratory cell storehouse, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: soft capsule for nasosinusitis of the present invention: prepare by embodiment 3 method.
Medicinal liquid liquid storage: take 100mg soft capsule for nasosinusitis, is dissolved in 5ml dehydrated alcohol, 0.2 μm of frit, 500 μ ldoff pipe subpackages ,-20 DEG C of storages, and simultaneously 0.2 μm of frit dehydrated alcohol is in order to the use of matched group.The control sample of Fructus Xanthii is prepared by same method.
1.3 experiment reagent
DMEM (GIBCO company Cat.No.12100-061Lot.No.758137); Hyclone (Tian Hang bio tech ltd, Zhejiang Lot.No.100419); NaHCO3 (Shanghai hundred million chemical reagent company limited Cat. No.11810-033Lot.No.1088387 of a specified duration); Trypsin (AMRESCO company lot number: 2010/04); EDTA (AMRESCO company lot number: 2009/10); Penicillin G Sodium Salt (AMRESCO company lot number: 2010242); Streptomycin Sulfate (AMRESCO company lot number: 2010382); Dehydrated alcohol (Nanjing Chemistry Reagent Co., Ltd.'s lot number: 080310182); MTT (Biosharp lot number: 0793); PBS (laboratory autogamy);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DM1L); Visible-ultraviolet light microwell plate detector (MD company of U.S. model: SPECTRA MAX190); CO2 incubator (FORMA model: 3111); Super-clean bench (safe and sound Inc. of Su Jing group moulding number: SW-CJ-ZFD); Pure water instrument (Spring company of U.S. model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (the accurate experimental facilities company in Shanghai model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μm of filter (MILLIPORE model: SLGP033RB); 10cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2 experimental techniques
1) SF295 cell DMEM+10%FBS in 37 DEG C, 5%CO2 carries out cellar culture (10cm culture dish), when Growth of Cells is to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 DEG C of digestion 2min, add 5ml complete medium neutralization reaction wherein, proceeded in centrifuge tube after piping and druming cell, the centrifugal 5min of 1000rpm, adjustment concentration of cell suspension 3 × 104/ml.
2) enter in 96 well culture plates by cell kind, every hole adds cell suspension 180 μ l, and culture plate puts into cell culture incubator (37 DEG C, 5%CO2) cellar culture.
3) according to cell growth status, generally grow to 50%-70%, add the control sample of soft capsule for nasosinusitis solution or Fructus Xanthii, continue to cultivate 24h.
4) add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT) after 24h, continue to cultivate 4h.
5) after 4h, buckle method removes supernatant, pats dry gently with absorbent paper, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on shaking table, crystal is fully dissolved.The light absorption value in each hole is measured at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add culture fluid) is set, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide) simultaneously, often organizes the multiple hole of setting 6.
7) result represents with the suppression ratio of medicine to cell:
Cell proliferation suppression ratio (%)=(control wells OD value-dosing holes OD value)/control wells OD value × 100%.Experiment repetition 3 times.
3 statistical dispositions
Adopt the correlation analysis in Microsoft Excel2003 software and Student t to check, data represent with mean ± S.D..
4 experimental results
Statistical result showed after mtt assay experiment, compare with matched group, when dosage reaches 5mg/ml, to SF295 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has pole significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 1 soft capsule for nasosinusitis is to SF295 cell inhibitory effect influence research (X ± SD)
Note: compare with matched group, * P<0.01; * P<0.001, compares with Herba Xanthii subgroup,
#p<0.01;
##p<0.001
5 experiment conclusion
Soft capsule for nasosinusitis can suppress SF295 cell proliferation, and reduce the Growth of Cells number of SF295 cell, this effect is dose dependent, and also has significant difference compared with single Herba Xanthii subgroup.
Test three: soft capsule for nasosinusitis of the present invention is on the impact of mice with constipation Small intestine advance activity
1, animal: healthy ICR mice, male and female half and half, heavy 18-22g, is provided by Nanjing Medical University's animal center, production licence number SCXK (Soviet Union) 2002-0031.
2, medicine and reagent: prepare soft capsule for nasosinusitis of the present invention by above-described embodiment 3, namely gets Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g joins CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 20MPa, temperature 40 DEG C, CO
2flow 2m1/g crude drug min, extraction time 160min, obtain supercritical extract, add soybean oil appropriate, mixing, grind with colloid mill, be chilled to room temperature, be pressed into soft capsule 1000, dry, deoil, dry, obtain 1000 soft capsules, 0.3 gram every, containing crude drug 1.8g in every soft capsule, thered is provided by Yunnan Yunlong Pharmaceutical Co., Ltd., lot number 20140611, clinical people's consumption per day is each 10, namely clinical people's consumption per day is 18g crude drug, therefore determine that every mice consumption is 18x0.0026=0.05g crude drug, with a kilogram calculating, dosage is 2.5g crude drug/kg, this is low dosage, dosage 5g crude drug/kg is middle dosage, dosage 10g crude drug/kg is high dose.Phenolphthalein tablets (phenolphthalein sugar-tablet), Junan, Shandong Province pharmaceutical factory, specification: 100mg*100 sheet/box, lot number 20140506, people's consumption per day 0.8g/ days, being equivalent to every mice consumption is 0.8gx0.0026=0.002g, with a kilogram calculating, dosage is 0.1g/kg, and with 3 times amount for dosage, namely positive group gives phenolphthalein tablets 0.3g/kg.All the other reagent are domestic analytical pure.R-1132, Wujin pharmaceutical factory, 20130724.
3, process of the test: get ICR mice 60, with the modeling of R-1132 50m/kg gavage, continuous 10 days, period normal diet, form Constipation Model, random packet, often organize about 10, male and female half and half, be divided into normal group, model group, positive drug group, soft capsule of the present invention is high, in, low three dosage groups, administration is the same, successive administration 14d, before experiment, water 12h is can't help in fasting, 2h after last administration, gavage with the charcoal end arabic gum suspension lml/g that volume fraction is 5% respectively, each group of mice is put to death after 20min, cut open the belly and measure every Mus small intestinal charcoal end displacement and total small intestinal length, be converted into the percentage rate that charcoal end displacement accounts for total small intestinal length, t test and judge group difference, the results are shown in Table 2.
Table 2 soft capsule of the present invention is on the impact (n=10) of mice with constipation Small intestine advance activity
Compare with model group, * * P<0.01*P<0.05, compares with positive drug group, ##P<0.01#P<0.05
4, result: medicine group of the present invention compares with model group, have and obviously promote mice with constipation Small intestine advance activity, promote gastrointestinal motility in mice, there is significant difference, compare with positive drug, medicine senior middle school of the present invention dosage group has significant difference in promotion mice with constipation Small intestine advance activity, and effect is better than positive drug.
Claims (3)
1. the application of soft capsule for nasosinusitis in preparation suppression human glioma cell SF295 cell proliferation, it is characterized in that soft capsule for nasosinusitis is made up as crude drug in right amount of Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g, soybean oil, preparation method is made up of the following step: get Fructus Xanthii 1344g, Flos Magnoliae 252g, Flos Lonicerae 84g, Radix Rubiae 84g, Flos Chrysanthemi Indici 84g join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO
2flow 1-3m1/g crude drug min, extraction time 150-180min, obtains supercritical extract, adds soybean oil in right amount, mixing, with colloid mill grinding, is chilled to room temperature, is pressed into soft capsule 1000, dry, deoils, dries, to obtain final product.
2. a kind of soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation according to claim 1, it is characterized in that CO described in soft capsule for nasosinusitis preparation method
2the percent by volume that supercritical extraction entrainer accounts for total extractant is 5%.
3. a kind of soft capsule for nasosinusitis suppresses the application in human glioma cell SF295 cell proliferation in preparation according to claim 1, it is characterized in that CO described in soft capsule for nasosinusitis preparation method
2the extracting pressure 20MPa of supercritical extraction, temperature 40 DEG C, CO
2flow 2ml/g crude drug min, extraction time 160min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410169286.6A CN103919885B (en) | 2014-04-25 | 2014-04-25 | A kind of preparation method of soft capsule for nasosinusitis and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410169286.6A CN103919885B (en) | 2014-04-25 | 2014-04-25 | A kind of preparation method of soft capsule for nasosinusitis and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103919885A CN103919885A (en) | 2014-07-16 |
| CN103919885B true CN103919885B (en) | 2015-09-30 |
Family
ID=51138427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410169286.6A Active CN103919885B (en) | 2014-04-25 | 2014-04-25 | A kind of preparation method of soft capsule for nasosinusitis and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919885B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840797A (en) * | 2015-05-28 | 2015-08-19 | 吉林省正和药业集团股份有限公司 | Preparation method and application of Yixuanning capsule |
| FR3145287A1 (en) | 2023-01-31 | 2024-08-02 | Le Rouge Français | Particular process for preparing an extract of at least one plant belonging to the Rubiaceae family. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634263A (en) * | 2004-11-03 | 2005-07-06 | 贵州海泰药业技术有限公司 | Soft capsule for nasosinusitis and its preparation |
| CN101569677A (en) * | 2009-03-16 | 2009-11-04 | 云南云龙制药有限公司 | Chinese patent medicament for treating conjunctival congestion and preparation method thereof |
| KR101417261B1 (en) * | 2012-04-16 | 2014-07-09 | 김현정 | Korean medical composition set for improving rhinitis and empyema and manufacturing method thereof |
| CN103494885B (en) * | 2013-10-11 | 2016-01-20 | 江西杏林白马药业有限公司 | A kind of preparation method of TONGXIAO BIYAN PIAN and application |
-
2014
- 2014-04-25 CN CN201410169286.6A patent/CN103919885B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103919885A (en) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494878A (en) | Preparation method and application of compound danshen tablets | |
| CN102988480B (en) | Method for preparing bile and patchouli rhinitis tablets and application | |
| CN102988612B (en) | Preparation method and application of tablet for clearing away heat | |
| CN103495117B (en) | Preparation method and application of thrombus removing and collaterals dredging tablets | |
| CN102988489B (en) | Preparation method and application of nose comforting tablet | |
| CN102988545B (en) | Preparation method and application of Yulian tablet | |
| CN103919885B (en) | A kind of preparation method of soft capsule for nasosinusitis and application | |
| CN102988614B (en) | Preparation method and application of antiphlogosis tablet | |
| CN103494885B (en) | A kind of preparation method of TONGXIAO BIYAN PIAN and application | |
| CN102988479B (en) | Preparation method and application of anti-dazzling tablet | |
| CN102973749B (en) | Preparation method and applications of divaricate saposhnikovia-angelica archang lica rhinitis tablets | |
| CN103977391A (en) | Preparation method and applications of bupleurum tenue capsule | |
| CN103479749B (en) | Preparation method and application of Gegenqinlian tablet | |
| CN102988611B (en) | Preparation method and application of antihypertension tablet | |
| CN102988500B (en) | Method for preparing compound Dantong tablets and application | |
| CN102988522B (en) | Preparation method and application of naodesheng tablets | |
| CN103735785B (en) | Pure and impure of ferrum broom suppresses the application in lymphoma cell YAC-1 cell proliferation in preparation | |
| CN103705825B (en) | Pure and impure of ferrum broom suppresses the application in teratocarcinoma cell F9 cell proliferation in preparation | |
| CN102988691B (en) | Preparation method and application of liver-strengthening tablet | |
| CN102988836B (en) | Preparation method and application of Fuganning tablets | |
| CN103690863B (en) | The application in check melanin oncocyte B16 cell proliferation prepared by pure and impure of ferrum broom | |
| CN102988576B (en) | Preparation method and application of nine-ingredient notopterygium root tablets | |
| CN104288657A (en) | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse teratoma cell P19 | |
| CN104288659A (en) | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse breast tumor cell C127 | |
| CN105726669A (en) | Application of lawn pennywort herb Yugan tablet to preparation of drugs for inhibiting lung adenocarcinoma cell H1299 proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 5 Jinghong Road, Changhong Community, Ala Street Office, Kunming Economic Development Zone, China (Yunnan) Pilot Free Trade Zone, Kunming City, Yunnan Province, 650217 Patentee after: YUNNAN YUNLONG PHARMACEUTICAL Co.,Ltd. Address before: No.5 Jinghong Road, Kunming Economic and Technological Development Zone, Yunnan Province Patentee before: YUNNAN YUNLONG PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |